Crixivan

What are the side effects you encounter while taking this medicine?
advertisement

Crixivan uses


DESCRIPTION

Crixivan® is an inhibitor of the human immunodeficiency virus (HIV) protease. Crixivan Capsules are formulated as a sulfate salt and are available for oral administration in strengths of 200 and 400 mg of indinavir (corresponding to 250 and 500 mg Crixivan, respectively). Each capsule also contains the inactive ingredients anhydrous lactose and magnesium stearate. The capsule shell has the following inactive ingredients and dyes: gelatin and titanium dioxide.

The chemical name for Crixivan is [1(1S,2R),5(S)]-2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-[2-[[(1,1-dimethylethyl)amino]carbonyl]-4-(3-pyridinylmethyl)-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide sulfate (1:1) salt. Crixivan has the following structural formula:

Study 028, a double-blind, multicenter, randomized, clinical endpoint trial conducted in Brazil, compared the effects of Crixivan plus zidovudine with those of Crixivan alone or zidovudine alone on the progression to an ADI or death, and on surrogate marker responses. All patients were antiretroviral naive with CD4 cell counts of 50 to 250 cells/mm3. The study enrolled 996 HIV-1 seropositive patients [28% female, 11% Black, 1% Asian/Other, median age 33 years, mean baseline CD4 cell count of 152 cells/mm3, mean serum viral RNA of 4.44 log10 copies/mL (27,824 copies/mL)]. Treatment regimens containing zidovudine were modified in a blinded manner with the optional addition of lamivudine (median time: week 40). The median length of follow-up was 56 weeks with a maximum of 97 weeks. The study was terminated after a planned interim analysis, resulting in a median follow-up of 56 weeks and a maximum follow-up of 97 weeks. Results are shown in Table 5 and Figures 3 and 4.

Number (%) of Patients with AIDS-defining Illness or Death
Endpoint IDV+ZDV

(n=332)

IDV

(n=332)

ZDV

(n=332)

HIV Progression or Death 21 (6.3) 27 (8.1) 62 (18.7)
DeathThe number of deaths is inadequate to assess the impact of Indinavir on survival. 8 (2.4) 5 (1.5) 11 (3.3)

Study 035 was a multicenter, randomized trial in 97 HIV-1 seropositive patients who were zidovudine-experienced (median exposure 30 months), protease-inhibitor- and lamivudine-naive, with mean baseline CD4 count 175 cells/mm3 and mean baseline serum viral RNA 4.62 log10 copies/mL (41,230 copies/mL). Comparisons included Crixivan plus zidovudine plus lamivudine vs. Crixivan alone vs. zidovudine plus lamivudine. After at least 24 weeks of randomized, double-blind therapy, patients were switched to open-label Crixivan plus lamivudine plus zidovudine. Mean changes in log10 viral RNA in serum, the proportions of patients with viral RNA below 500 copies/mL in serum, and mean changes in CD4 cell counts, during 24 weeks of randomized, double-blinded therapy are summarized in Figures 5, 6, and 7, respectively. A limited number of patients remained on randomized, double-blind treatment for longer periods; based on this extended treatment experience, it appears that a greater number of subjects randomized to Crixivan plus zidovudine plus lamivudine demonstrated HIV RNA levels below 500 copies/mL during one year of therapy as compared to those in other treatment groups.

Genotypic Resistance in Clinical Studies

Study 006 (10/15/93-10/12/94) was a dose-ranging study in which patients were initially treated with Crixivan at a dose of <2.4 g/day followed by 2.4 g/day. Study 019 (6/23/94-4/10/95) was a randomized comparison of Crixivan 600 mg every 6 hours, Crixivan plus zidovudine, and zidovudine alone. Table 6 shows the incidence of genotypic resistance at 24 weeks in these studies.

Treatment Group Resistance

to IDV

n/NN - includes patients with non-amplifiable virus at 24 weeks who had amplifiable virus at week 0.

Resistance

to ZDV

n/N

IDV - -
<2.4 g/day 31/37 (84%) -
2.4 g/day 9/21 (43%) 1/17 (6%)
IDV/ZDV 4/22 (18%) 1/22 (5%)
ZDV 1/18 (6%) 11/17 (65%)
image of study ACTG 320 figure 1 image of study ACTG 320 Figure 2 image of study 028 figure 3 image of study 028 figure 4 image of study 035 figure 5 image of study 035 figure 6 image of study 035 figure 7
advertisement

CONTRAINDICATIONS

Crixivan is contraindicated in patients with clinically significant hypersensitivity to any of its components.

Inhibition of CYP3A4 by Crixivan can result in elevated plasma concentrations of the following drugs, potentially causing serious and/or life-threatening reactions:

Drug Class Drugs Within Class That Are Contraindicated With Crixivan
Alpha 1-adrenoreceptor antagonist alfuzosin
Antiarrhythmics amiodarone
Antipsychotics lurasidone, pimozide
Ergot derivatives dihydroergotamine, ergonovine, ergotamine, methylergonovine
GI motility agents cisapride
HMG-CoA Reductase Inhibitors lovastatin, simvastatin
PDE5 Inhibitors RevatioRegistered trademark of Pfizer, Inc. (sildenafil) [for treatment of pulmonary arterial hypertension]
Sedative/hypnotics oral midazolam, triazolam, alprazolam
advertisement

WARNINGS

ALERT: Find out about medicines that should NOT be taken with Crixivan. This statement is included on the product's bottle label.

Nephrolithiasis/Urolithiasis

Nephrolithiasis/urolithiasis has occurred with Crixivan therapy. The cumulative frequency of nephrolithiasis is substantially higher in pediatric patients than in adult patients (12.4%; range across individual trials: 4.7% to 34.4%). The cumulative frequency of nephrolithiasis events increases with increasing exposure to Crixivan; however, the risk over time remains relatively constant. In some cases, nephrolithiasis/urolithiasis has been associated with renal insufficiency or acute renal failure, pyelonephritis with or without bacteremia. If signs or symptoms of nephrolithiasis/urolithiasis occur, (including flank pain, with or without hematuria or microscopic hematuria), temporary interruption (e.g., 1-3 days) or discontinuation of therapy may be considered. Adequate hydration is recommended in all patients treated with Crixivan.

Hemolytic Anemia

Acute hemolytic anemia, including cases resulting in death, has been reported in patients treated with Crixivan. Once a diagnosis is apparent, appropriate measures for the treatment of hemolytic anemia should be instituted, including discontinuation of Crixivan.

Hepatitis

Hepatitis including cases resulting in hepatic failure and death has been reported in patients treated with Crixivan. Because the majority of these patients had confounding medical conditions and/or were receiving concomitant therapy, a causal relationship between Crixivan and these events has not been established.

Hyperglycemia

New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus and hyperglycemia have been reported during post-marketing surveillance in HIV-infected patients receiving protease inhibitor therapy. Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. In some cases, diabetic ketoacidosis has occurred. In those patients who discontinued protease inhibitor therapy, hyperglycemia persisted in some cases. Because these events have been reported voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established.

Risk of Serious Adverse Reactions Due to Drug Interactions

Initiation of Crixivan, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Crixivan, may increase plasma concentrations of medications metabolized by CYP3A. Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of Crixivan, respectively. These interactions may lead to:


Concomitant use of Crixivan with lovastatin or simvastatin is contraindicated due to an increased risk of myopathy including rhabdomyolysis. Caution should be exercised if Crixivan is used concurrently with atorvastatin or rosuvastatin. Titrate the atorvastatin and rosuvastatin doses carefully and use the lowest necessary dose with Crixivan.

Midazolam is extensively metabolized by CYP3A4. Co-administration with Crixivan with or without ritonavir may cause a large increase in the concentration of this benzodiazepine. No drug interaction study has been performed for the co-administration of Crixivan with benzodiazepines. Based on data from other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally. Therefore Crixivan should not be co-administered with orally administered midazolam, whereas caution should be used with co-administration of Crixivan and parenteral midazolam. Data from concomitant use of parenteral midazolam with other protease inhibitors suggest a possible 3-4 fold increase in midazolam plasma levels. If Crixivan with or without ritonavir is co-administered with parenteral midazolam, it should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.

Particular caution should be used when prescribing sildenafil, tadalafil, or vardenafil in patients receiving indinavir. Coadministration of Crixivan with these medications is expected to substantially increase plasma concentrations of sildenafil, tadalafil, and vardenafil and may result in an increase in adverse events, including hypotension, visual changes, and priapism, which have been associated with sildenafil, tadalafil, and vardenafil.

Concomitant use of Crixivan and St. John's wort (Hypericum perforatum) or products containing St. John's wort is not recommended. Coadministration of Crixivan and St. John's wort has been shown to substantially decrease indinavir concentrations and may lead to loss of virologic response and possible resistance to Crixivan or to the class of protease inhibitors.

advertisement

PRECAUTIONS

General

Indirect hyperbilirubinemia has occurred frequently during treatment with Crixivan and has infrequently been associated with increases in serum transaminases. It is not known whether Crixivan will exacerbate the physiologic hyperbilirubinemia seen in neonates.

Tubulointerstitial Nephritis

Reports of tubulointerstitial nephritis with medullary calcification and cortical atrophy have been observed in patients with asymptomatic severe leukocyturia (>100 cells/ high power field). Patients with asymptomatic severe leukocyturia should be followed closely and monitored frequently with urinalyses. Further diagnostic evaluation may be warranted, and discontinuation of Crixivan should be considered in all patients with severe leukocyturia.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including Crixivan. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.

Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.

Coexisting Conditions

Patients with hemophilia: There have been reports of spontaneous bleeding in patients with hemophilia A and B treated with protease inhibitors. In some patients, additional factor VIII was required. In many of the reported cases, treatment with protease inhibitors was continued or restarted. A causal relationship between protease inhibitor therapy and these episodes has not been established.

Patients with hepatic insufficiency due to cirrhosis: In these patients, the dosage of Crixivan should be lowered because of decreased metabolism of Crixivan.

Patients with renal insufficiency: Patients with renal insufficiency have not been studied.

Fat Redistribution

Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and "cushingoid appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.

Information for Patients

A statement to patients and health care providers is included on the product's bottle label. ALERT: Find out about medicines that should NOT be taken with Crixivan. A Patient Package Insert for Crixivan is available for patient information.

Crixivan is not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician when using Crixivan.

Patients should be advised to avoid doing things that can spread HIV-1 infection to others.


Patients should be advised to remain under the care of a physician when using Crixivan and should not modify or discontinue treatment without first consulting the physician. Therefore, if a dose is missed, patients should take the next dose at the regularly scheduled time and should not double this dose. Therapy with Crixivan should be initiated and maintained at the recommended dosage.

Crixivan may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St. John's wort.

For optimal absorption, Crixivan should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, Crixivan may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal, e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; or corn flakes, skim milk and sugar. Ingestion of Crixivan with a meal high in calories, fat, and protein reduces the absorption of indinavir.

Patients receiving a phosphodiesterase type 5 (PDE5) inhibitor (sildenafil, tadalafil, or vardenafil) should be advised that they may be at an increased risk of PDE5 inhibitor-associated adverse events including hypotension, visual changes, and priapism, and should promptly report any symptoms to their doctors.

Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time.

Crixivan Capsules are sensitive to moisture. Patients should be informed that Crixivan should be stored and used in the original container and the desiccant should remain in the bottle.

Drug Interactions

Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration of Crixivan and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects.

Indinavir is metabolized by CYP3A4. Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir. Coadministration of Crixivan and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.

Drug Class: Drug Name Clinical Comment
Alpha 1-adrenoreceptor antagonist:

alfuzosin

Potentially increased alfuzosin concentrations can result in hypotension.
Antiarrhythmics:

amiodarone

CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Antimycobacterial:

rifampin

May lead to loss of virologic response and possible resistance to Crixivan or to the class of protease inhibitors or other coadministered antiretroviral agents.
Antipsychotics:

lurasidone

pimozide


CONTRAINDICATED due to potential for serious and/or life-threatening reactions.

CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.

Ergot derivatives:

dihydroergotamine, ergonovine,

ergotamine, methylergonovine

CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
GI motility agents:

cisapride

CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Herbal products:

St. John's wort (Hypericum perforatum)

May lead to loss of virologic response and possible resistance to Crixivan or to the class of protease inhibitors.
HMG-CoA Reductase inhibitors:

lovastatin, simvastatin

CONTRAINDICATED due to an increased risk for serious reactions such as myopathy including rhabdomyolysis.
PDE5 inhibitor:

RevatioRegistered trademark of Pfizer, Inc. (sildenafil) [for treatment of pulmonary arterial hypertension]

A safe and effective dose has not been established when used with Crixivan. There is increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, prolonged erection, and syncope).
Protease inhibitor:

atazanavir

Both Crixivan and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia. Combinations of these drugs have not been studied and coadministration of Crixivan and atazanavir is not recommended.
Sedative/hypnotics:

Oral midazolam, triazolam, alprazolam

CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
Drug Name Effect Clinical Comment
HIV Antiviral Agents
Note: ↑ = increase; ↓ = decrease
Delavirdine ↑ indinavir concentration Dose reduction of Crixivan to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
Didanosine Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.
Efavirenz ↓ indinavir concentration The optimal dose of indinavir, when given in combination with efavirenz, is not known. Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.
Nelfinavir ↑ indinavir concentration The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
Nevirapine ↓ indinavir concentration Indinavir concentrations may be decreased in the presence of nevirapine. The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
Ritonavir ↑ indinavir concentration

↑ ritonavir concentration

The appropriate doses for this combination, with respect to efficacy and safety, have not been established. Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving Crixivan 800 mg q8h.
Saquinavir ↑ saquinavir concentration The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
Other Agents
Antiarrhythmics:

bepridil, lidocaine(systemic)

and quinidine

↑ antiarrhythmic agents concentration Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with Crixivan.
Anticonvulsants:

carbamazepine, phenobarbital,

phenytoin

↓ indinavir concentration Use with caution. Crixivan may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.
Antidepressant:

Trazodone

↑ trazodone concentration Concomitant use of trazodone and Crixivan may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as Crixivan, the combination should be used with caution and a lower dose of trazodone should be considered.
Anti-gout:

Colchicine

↑ colchicine concentration Patients with renal or hepatic impairment should not be given colchicine with Crixivan.

Treatment of gout flares:

Co-administration of colchicine in patients on Crixivan: 0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.

Prophylaxis of gout flares:

Co-administration of colchicine in patients on Crixivan:

If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.

If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.

Treatment of familial Mediterranean fever (FMF):

Co-administration of colchicine in patients on Crixivan: Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).

Antipsychotics:

Quetiapine

↑ quetiapine Initiation of Crixivan in patients taking quetiapine:

Consider alternative antiretroviral therapy to avoid increases in quetiapine drug exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.

Initiation of quetiapine in patients taking Crixivan:

Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.

Calcium Channel Blockers,

Dihydropyridine: e.g., felodipine,

nifedipine, nicardipine

↑ dihydropyridine calcium channel blockers concentration Caution is warranted and clinical monitoring of patients is recommended.
Clarithromycin ↑ clarithromycin concentration

↑ indinavir concentration

The appropriate doses for this combination, with respect to efficacy and safety, have not been established.
Endothelin receptor antagonist:

Bosentan

↑ bosentan concentration Co-administration of bosentan in patients on Crixivan or co-administration of Crixivan in patients on bosentan: Start at or adjust bosentan to 62.5 mg once daily or every other day based upon individual tolerability.
HMG-CoA Reductase

Inhibitors: atorvastatin,

rosuvastatin

↑ atorvastatin concentration

↑ rosuvastatin concentration

The atorvastatin and rosuvastatin doses should be carefully titrated; use the lowest dose necessary with careful monitoring during treatment with Crixivan.
Immunosuppressants: cyclosporine, tacrolimus, sirolimus ↑ immunosuppressant agents concentration Plasma concentrations may be increased by Crixivan.
Inhaled beta agonist:

Salmeterol

↑ salmeterol Concurrent administration of salmeterol with Crixivan is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Inhaled/nasal steroid:

Fluticasone

↑ fluticasone concentration Concomitant use of fluticasone propionate and Crixivan may increase plasma concentrations of fluticasone propionate. Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.

Fluticasone use is not recommended in situations where Crixivan is coadministered with a potent CYP3A4 inhibitor such as ritonavir unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.

Itraconazole ↑ indinavir concentration Dose reduction of Crixivan to 600 mg every 8 hours is recommended when administering itraconazole concurrently.
Ketoconazole ↑ indinavir concentration Dose reduction of Crixivan to 600 mg every 8 hours should be considered.
Midazolam (parenteral administration) ↑ midazolam concentration Concomitant use of parenteral midazolam with Crixivan may increase plasma concentrations of midazolam. Coadministration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Coadministration of oral midazolam with Crixivan is CONTRAINDICATED.
Rifabutin ↓ indinavir concentration

↑ rifabutin concentration

Dose reduction of rifabutin to half the standard dose and a dose increase of Crixivan to 1000 mg every 8 hours are recommended when rifabutin and Crixivan are coadministered.
Sildenafil ↑ sildenafil concentration

(only the use of sildenafil at doses used for treatment of erectile dysfunction has been studied with Crixivan)

May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.

Use of sildenafil for pulmonary arterial hypertension (PAH):

Use of RevatioRegistered trademark of Pfizer, Inc. (sildenafil) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH).

Use of sildenafil for erectile dysfunction:

Sildenafil dose should not exceed a maximum of 25 mg in a 48-hour period in patients receiving concomitant Crixivan therapy. Use with increased monitoring for adverse events.

Tadalafil ↑ tadalafil concentration May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, visual disturbances, and priapism.

Use of tadalafil for pulmonary arterial hypertension (PAH):

The following dose adjustments are recommended for use of AdcircaRegistered trademark of Eli Lilly and Company. (tadalafil) with Crixivan:

Co-administration of Adcirca in patients on Crixivan or co-administration of Crixivan in patients on Adcirca:

Start at or adjust Adcirca to 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.

Use of tadalafil for erectile dysfunction:

Tadalafil dose should not exceed a maximum of 10 mg in a 72-hour period in patients receiving concomitant Crixivan therapy. Use with increased monitoring for adverse events.

Vardenafil ↑ vardenafil concentration Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
Venlafaxine ↓ indinavir concentration In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies were conducted in mice and rats. In mice, no increased incidence of any tumor type was observed. The highest dose tested in rats was 640 mg/kg/day; at this dose a statistically significant increased incidence of thyroid adenomas was seen only in male rats. At that dose, daily systemic exposure in rats was approximately 1.3 times higher than daily systemic exposure in humans. No evidence of mutagenicity or genotoxicity was observed in in vitro microbial mutagenesis tests, in vitro alkaline elution assays for DNA breakage, in vitro and in vivo chromosomal aberration studies, and in vitro mammalian cell mutagenesis assays. No treatment-related effects on mating, fertility, or embryo survival were seen in female rats and no treatment-related effects on mating performance were seen in male rats at doses providing systemic exposure comparable to or slightly higher than that with the clinical dose. In addition, no treatment-related effects were observed in fecundity or fertility of untreated females mated to treated males.

Pregnancy

Pregnancy Category C:

Developmental toxicity studies were performed in rabbits, dogs (at doses up to 80 mg/kg/day), and rats (at doses up to 640 mg/kg/day). The highest doses in these studies produced systemic exposures in these species comparable to or slightly greater than human exposure. No treatment-related external, visceral, or skeletal changes were observed in rabbits or dogs. No treatment-related external or visceral changes were observed in rats. Treatment-related increases over controls in the incidence of supernumerary ribs (at exposures at or below those in humans) and of cervical ribs (at exposures comparable to or slightly greater than those in humans) were seen in rats. In all three species, no treatment-related effects on embryonic/fetal survival or fetal weights were observed.

In rabbits, at a maternal dose of 240 mg/kg/day, no drug was detected in fetal plasma 1 hour after dosing. Fetal plasma drug levels 2 hours after dosing were approximately 3% of maternal plasma drug levels. In dogs, at a maternal dose of 80 mg/kg/day, fetal plasma drug levels were approximately 50% of maternal plasma drug levels both 1 and 2 hours after dosing. In rats, at maternal doses of 40 and 640 mg/kg/day, fetal plasma drug levels were approximately 10 to 15% and 10 to 20% of maternal plasma drug levels 1 and 2 hours after dosing, respectively.

Indinavir was administered to Rhesus monkeys during the third trimester of pregnancy (at doses up to 160 mg/kg twice daily) and to neonatal Rhesus monkeys (at doses up to 160 mg/kg twice daily). When administered to neonates, indinavir caused an exacerbation of the transient physiologic hyperbilirubinemia seen in this species after birth; serum bilirubin values were approximately fourfold above controls at 160 mg/kg twice daily. A similar exacerbation did not occur in neonates after in utero exposure to indinavir during the third trimester of pregnancy. In Rhesus monkeys, fetal plasma drug levels were approximately 1 to 2% of maternal plasma drug levels approximately 1 hour after maternal dosing at 40, 80, or 160 mg/kg twice daily.

Hyperbilirubinemia has occurred during treatment with Crixivan. It is unknown whether Crixivan administered to the mother in the perinatal period will exacerbate physiologic hyperbilirubinemia in neonates.

There are no adequate and well-controlled studies in pregnant patients. Crixivan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

A Crixivan dose of 800 mg every 8 hours (with zidovudine 200 mg every 8 hours and lamivudine 150 mg twice a day) has been studied in 16 HIV-infected pregnant patients at 14 to 28 weeks of gestation at enrollment (study PACTG 358). Given the substantially lower antepartum exposures observed and the limited data in this patient population, indinavir use is not recommended in HIV-infected pregnant patients.

Antiretroviral Pregnancy Registry

To monitor maternal-fetal outcomes of pregnant patients exposed to Crixivan, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.

Nursing Mothers

Studies in lactating rats have demonstrated that indinavir is excreted in milk. Although it is not known whether Crixivan is excreted in human milk, there exists the potential for adverse effects from indinavir in nursing infants. Mothers should be instructed to discontinue nursing if they are receiving Crixivan. This is consistent with the recommendation by the U.S. Public Health Service Centers for Disease Control and Prevention that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV.

Pediatric Use

The optimal dosing regimen for use of indinavir in pediatric patients has not been established. A dose of 500 mg/m2 every eight hours has been studied in uncontrolled studies of 70 children, 3 to 18 years of age. The pharmacokinetic profiles of indinavir at this dose were not comparable to profiles previously observed in adults receiving the recommended dose. Although viral suppression was observed in some of the 32 children who were followed on this regimen through 24 weeks, a substantially higher rate of nephrolithiasis was reported when compared to adult historical data. Physicians considering the use of indinavir in pediatric patients without other protease inhibitor options should be aware of the limited data available in this population and the increased risk of nephrolithiasis.

Geriatric Use

Clinical studies of Crixivan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy.

advertisement

ADVERSE REACTIONS

Clinical Trials in Adults

Nephrolithiasis/urolithiasis, including flank pain with or without hematuria, has been reported in approximately 12.4% (301/2429; range across individual trials: 4.7% to 34.4%) of patients receiving Crixivan at the recommended dose in clinical trials with a median follow-up of 47 weeks (range: 1 day to 242 weeks; 2238 patient-years follow-up). The cumulative frequency of nephrolithiasis events increases with duration of exposure to Crixivan; however, the risk over time remains relatively constant. Of the patients treated with Crixivan who developed nephrolithiasis/urolithiasis in clinical trials during the double-blind phase, 2.8% (7/246) were reported to develop hydronephrosis and 4.5% (11/246) underwent stent placement. Following the acute episode, 4.9% (12/246) of patients discontinued therapy.

Asymptomatic hyperbilirubinemia (total bilirubin ≥2.5 mg/dL), reported predominantly as elevated indirect bilirubin, has occurred in approximately 14% of patients treated with Crixivan. In <1% this was associated with elevations in ALT or AST.

Hyperbilirubinemia and nephrolithiasis/urolithiasis occurred more frequently at doses exceeding 2.4 g/day compared to doses ≤2.4 g/day.

Clinical adverse experiences reported in ≥2% of patients treated with Crixivan alone, Crixivan in combination with zidovudine or zidovudine plus lamivudine, zidovudine alone, or zidovudine plus lamivudine are presented in Table 10.

Study 028

Considered Drug-Related and of Moderate or Severe Intensity

Study ACTG 320

of Unknown Drug Relationship and of Severe or Life-threatening Intensity

Crixivan

Crixivan

plus

Zidovudine

Zidovudine

Crixivan plus

Zidovudine plus Lamivudine

Zidovudine

plus

Lamivudine

Adverse Experience Percent

(n=332)

Percent

(n=332)

Percent

(n=332)

Percent

(n=571)

Percent

(n=575)

Body as a Whole
Abdominal pain 16.6 16.0 12.0 1.9 0.7
Asthenia/fatigue 2.1 4.2 3.6 2.4 4.5
Fever 1.5 1.5 2.1 3.8 3.0
Malaise 2.1 2.7 1.8 0 0
Digestive System
Nausea 11.7 31.9 19.6 2.8 1.4
Diarrhea 3.3 3.0 2.4 0.9 1.2
Vomiting 8.4 17.8 9.0 1.4 1.4
Acid regurgitation 2.7 5.4 1.8 0.4 0
Anorexia 2.7 5.4 3.0 0.5 0.2
Appetite increase 2.1 1.5 1.2 0 0
Dyspepsia 1.5 2.7 0.9 0 0
Jaundice 1.5 2.1 0.3 0 0
Hemic and Lymphatic System
Anemia 0.6 1.2 2.1 2.4 3.5
Musculoskeletal System
Back pain 8.4 4.5 1.5 0.9 0.7
Nervous System/Psychiatric
Headache 5.4 9.6 6.0 2.4 2.8
Dizziness 3.0 3.9 0.9 0.5 0.7
Somnolence 2.4 3.3 3.3 0 0
Skin and Skin Appendage
Pruritus 4.2 2.4 1.8 0.5 0
Rash 1.2 0.6 2.4 1.1 0.5
Respiratory System
Cough 1.5 0.3 0.6 1.6 1.0
Difficulty breathing/

dyspnea/

shortness of breath

0 0.6 0.3 1.8 1.0
Urogenital System
Nephrolithiasis/urolithiasisIncluding renal colic, and flank pain with and without hematuria 8.7 7.8 2.1 2.6 0.3
Dysuria 1.5 2.4 0.3 0.4 0.2
Special Senses
Taste perversion 2.7 8.4 1.2 0.2 0

In Phase I and II controlled trials, the following adverse events were reported significantly more frequently by those randomized to the arms containing Crixivan than by those randomized to nucleoside analogues: rash, upper respiratory infection, dry skin, pharyngitis, taste perversion.

Selected laboratory abnormalities of severe or life-threatening intensity reported in patients treated with Crixivan alone, Crixivan in combination with zidovudine or zidovudine plus lamivudine, zidovudine alone, or zidovudine plus lamivudine are presented in Table 11.

Study 028 Study ACTG 320
Crixivan Crixivan

plus

Zidovudine

Zidovudine Crixivan plus

Zidovudine

plus

Lamivudine

Zidovudine

plus

Lamivudine

Percent

(n=329)

Percent

(n=320)

Percent

(n=330)

Percent

(n=571)

Percent

(n=575)

Hematology
Decreased hemoglobin

<7.0 g/dL

0.6 0.9 3.3 2.4 3.5
Decreased platelet count

<50 THS/mm3

0.9 0.9 1.8 0.2 0.9
Decreased neutrophils

<0.75 THS/mm3

2.4 2.2 6.7 5.1 14.6
Blood chemistry
Increased ALT

>500% ULNUpper limit of the normal range.

4.9 4.1 3.0 2.6 2.6
Increased AST

>500% ULN

3.7 2.8 2.7 3.3 2.8
Total serum bilirubin

>250% ULN

11.9 9.7 0.6 6.1 1.4
Increased serum amylase

>200% ULN

2.1 1.9 1.8 0.9 0.3
Increased glucose

>250 mg/dL

0.9 0.9 0.6 1.6 1.9
Increased creatinine

>300% ULN

0 0 0.6 0.2 0

Post-Marketing Experience

Body As A Whole: redistribution/accumulation of body fat.

Cardiovascular System: cardiovascular disorders including myocardial infarction and angina pectoris; cerebrovascular disorder.

Digestive System: liver function abnormalities; hepatitis including reports of hepatic failure ; pancreatitis; jaundice; abdominal distention; dyspepsia.

Hematologic: increased spontaneous bleeding in patients with hemophilia ; acute hemolytic anemia.

Endocrine/Metabolic: new onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, hyperglycemia.

Hypersensitivity: anaphylactoid reactions; urticaria; vasculitis.

Musculoskeletal System: arthralgia, periarthritis.

Nervous System/Psychiatric: oral paresthesia; depression.

Skin and Skin Appendage: rash including erythema multiforme and Stevens-Johnson syndrome; hyperpigmentation; alopecia; ingrown toenails and/or paronychia; pruritus.

Urogenital System: nephrolithiasis/urolithiasis, in some cases resulting in renal insufficiency or acute renal failure, pyelonephritis with or without bacteremia ; interstitial nephritis sometimes with indinavir crystal deposits; in some patients, the interstitial nephritis did not resolve following discontinuation of Crixivan; renal insufficiency; renal failure; leukocyturia, crystalluria; dysuria.

Laboratory Abnormalities

Increased serum triglycerides; increased serum cholesterol.

OVERDOSAGE

There have been more than 60 reports of acute or chronic human overdosage (up to 23 times the recommended total daily dose of 2400 mg) with Crixivan. The most commonly reported symptoms were renal (e.g., nephrolithiasis/urolithiasis, flank pain, hematuria) and gastrointestinal (e.g., nausea, vomiting, diarrhea).

It is not known whether Crixivan is dialyzable by peritoneal or hemodialysis.

DOSAGE AND ADMINISTRATION

The recommended dosage of Crixivan is 800 mg orally every 8 hours.

Crixivan must be taken at intervals of 8 hours. For optimal absorption, Crixivan should be administered without food but with water 1 hour before or 2 hours after a meal. Alternatively, Crixivan may be administered with other liquids such as skim milk, juice, coffee, or tea, or with a light meal, e.g., dry toast with jelly, juice, and coffee with skim milk and sugar; or corn flakes, skim milk and sugar.

To ensure adequate hydration, it is recommended that adults drink at least 1.5 liters (approximately 48 ounces) of liquids during the course of 24 hours.

Concomitant Therapy

Delavirdine

Dose reduction of Crixivan to 600 mg every 8 hours should be considered when administering delavirdine 400 mg three times a day.

Didanosine

If indinavir and didanosine are administered concomitantly, they should be administered at least one hour apart on an empty stomach.

Itraconazole

Dose reduction of Crixivan to 600 mg every 8 hours is recommended when administering itraconazole 200 mg twice daily concurrently.

Ketoconazole

Dose reduction of Crixivan to 600 mg every 8 hours is recommended when administering ketoconazole concurrently.

Rifabutin

Dose reduction of rifabutin to half the standard dose and a dose increase of Crixivan to 1000 mg every 8 hours are recommended when rifabutin and Crixivan are coadministered.

Hepatic Insufficiency

The dosage of Crixivan should be reduced to 600 mg every 8 hours in patients with mild-to-moderate hepatic insufficiency due to cirrhosis.

Nephrolithiasis/Urolithiasis

In addition to adequate hydration, medical management in patients who experience nephrolithiasis/urolithiasis may include temporary interruption (e.g., 1 to 3 days) or discontinuation of therapy.

HOW SUPPLIED

Crixivan Capsules are supplied as follows:

No. 3756 - 200 mg capsules: semi-translucent white capsules coded "CRIXIVAN 200 mg" in blue. Available as:

NDC 0006-0571-43 unit-of-use bottles of 360.

No. 3758 - 400 mg capsules: semi-translucent white capsules coded "CRIXIVAN 400 mg" in green. Available as:

NDC 0006-0573-62 unit-of-use bottles of 180 (with desiccant)

Storage

Bottles: Store in a tightly-closed container at room temperature, 15-30°C (59-86°F). Protect from moisture.

Crixivan Capsules are sensitive to moisture. Crixivan should be dispensed and stored in the original container. The desiccant should remain in the original bottle.

Dist. by: Merck Sharp & Dohme Corp., a subsidiary of

MERCK & CO., INC., Whitehouse Station, NJ 08889, USA

For patent information: www.merck.com/product/patent/home.html

Copyright © 1996-2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

All rights reserved.

Revised 09/2016

uspi-mk0639-c-1609r018

Crixivan® (indinavir sulfate) Capsules

Patient Information about

Crixivan (KRIK-sih-van)

for HIV (Human Immunodeficiency Virus) Infection

Generic name: indinavir (in-DIH-nuh-veer) sulfate

ALERT: Find out about medicines that should NOT be taken with Crixivan®. Please also read the section "MEDICINES YOU SHOULD NOT TAKE WITH CRIXIVAN".

Please read this information before you start taking Crixivan. Also, read the leaflet each time you renew your prescription, just in case anything has changed. Remember, this leaflet does not take the place of careful discussions with your doctor. You and your doctor should discuss Crixivan when you start taking your medication and at regular checkups. You should remain under a doctor's care when using Crixivan and should not change or stop treatment without first talking with your doctor.

What is Crixivan?

Crixivan is an oral capsule used for the treatment of HIV. HIV is the virus that causes AIDS (acquired immune deficiency syndrome). Crixivan is a type of HIV drug called a protease (PRO-tee-ase) inhibitor.

How does Crixivan work?

Crixivan is a protease inhibitor that fights HIV. Crixivan can help reduce your chances of getting illnesses associated with HIV. Crixivan can also help lower the amount of HIV in your body (called "viral load") and raise your CD4 (T) cell count. Crixivan may not have these effects in all patients.

Crixivan is usually prescribed with other anti-HIV drugs such as ZDV (also called AZT), 3TC, ddI, ddC, or d4T. Crixivan works differently from these other anti-HIV drugs. Talk with your doctor about how you should take Crixivan.

How should I take Crixivan?

There are six important things you must do to help you benefit from Crixivan:

Does Crixivan cure HIV or AIDS?

Crixivan does not cure HIV infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using Crixivan.

Avoid doing things that can spread HIV-1 infection.

Who should not take Crixivan?

Do not take Crixivan if you have had a serious allergic reaction to Crixivan or any of its components.

What other medical problems or conditions should I discuss with my doctor?

Talk to your doctor if:


Also talk to your doctor if you have:


Tell your doctor about any medicines you are taking or plan to take, including non-prescription medicines, herbal products including St. John's wort, or dietary supplements.

Can Crixivan be taken with other medications?

MEDICINES YOU SHOULD NOT TAKE WITH Crixivan

Oral VERSED®

(midazolam)

HALCION®

(triazolam)

ORAP®

(pimozide)

XANAX®

(alprazolam)

PROPULSID®

(cisapride)

REVATIO®

(sildenafil for the treatment of pulmonary arterial hypertension)

CORDARONE®

(amiodarone)

UROXATRAL®

(alfuzosin)

HISMANAL®

(astemizole)

Ergot medications

(e.g., Wigraine®, Cafergot®, D.H.E. 45®, Migranal®, Ergotrate®, and Methergine®)

ZOCOR® (simvastatin)

MEVACOR® (lovastatin)

LATUDA® (lurasidone)


Taking Crixivan with the above medications could result in serious or life-threatening problems (such as irregular heartbeat or excessive sleepiness).

In addition, you should not take Crixivan with the following:


Before you take VIAGRA® (sildenafil), CIALIS® (tadalafil), or LEVITRA® (vardenafil) with Crixivan, talk to your doctor about possible drug interactions and side effects. If you take any of these medicines together with Crixivan, you may be at increased risk of side effects such as low blood pressure, visual changes, and penile erection lasting more than 4 hours, which have been associated with sildenafil, tadalafil, and vardenafil. If an erection lasts longer than 4 hours, you should seek immediate medical assistance to avoid permanent damage to your penis. Your doctor can explain these symptoms to you.

MEDICINES YOU CAN TAKE WITH Crixivan

RETROVIR®

(zidovudine, ZDV also called AZT)

EPIVIR

(lamivudine, 3TC)

ZERIT®

(stavudine, d4T)

isoniazid

(INH)

BACTRIM®/SEPTRA®

(trimethoprim/sulfamethoxazole)

DIFLUCAN®

(fluconazole)

BIAXIN®

(clarithromycin)

ORTHO-NOVUM 1/35®

(oral contraceptive)

TAGAMET®

(cimetidine)

Methadone

VIDEX® (didanosine, ddI) - If you take Crixivan with VIDEX, take them at least one hour apart.


MYCOBUTIN® (rifabutin) - If you take Crixivan with MYCOBUTIN, your doctor may adjust both the dose of MYCOBUTIN and the dose of Crixivan.


NIZORAL® (ketoconazole) - If you take Crixivan with NIZORAL, your doctor may adjust the dose of Crixivan.


RESCRIPTOR® (delavirdine) - If you take Crixivan with RESCRIPTOR, your doctor may adjust the dose of Crixivan.


SPORANOX® (itraconazole) - If you take Crixivan with SPORANOX, your doctor may adjust the dose of Crixivan.


SUSTIVA (efavirenz) - If you take Crixivan with SUSTIVA, check with your doctor.

Intravenous VERSED® (midazolam) - If you take Crixivan with Intravenous VERSED®, your doctor may adjust the dose of VERSED®.

Talk to your doctor about any medications you are taking.

Antipsychotics: Tell your doctor if you are taking antipsychotics (e.g., quetiapine).

Calcium Channel Blockers: Tell your doctor if you are taking calcium channel blockers (e.g., amlodipine, felodipine).

Antiarrhythmics: Tell your doctor if you are taking antiarrhythmics (e.g., quinidine).

Anticonvulsants: Tell your doctor if you are taking anticonvulsants (e.g., phenobarbital, phenytoin, or carbamazepine).

Steroids: Tell your doctor if you are taking steroids (e.g., dexamethasone).

What are the possible side effects of Crixivan?

Like all prescription drugs, Crixivan can cause side effects. The following is not a complete list of side effects reported with Crixivan when taken either alone or with other anti-HIV drugs. Do not rely on this leaflet alone for information about side effects. Your doctor can discuss with you a more complete list of side effects.

Some patients treated with Crixivan developed kidney stones. In some of these patients this led to more severe kidney problems, including kidney failure or inflammation of the kidneys or kidney infection which sometimes spread to the blood. Drinking at least six 8-ounce glasses of liquids (preferably water) each day should help reduce the chances of forming a kidney stone ( see How should I take Crixivan? ). Call your doctor or other health care provider if you develop kidney pains (middle to lower stomach or back pain) or blood in the urine.

Some patients treated with Crixivan have had rapid breakdown of red blood cells (hemolytic anemia) which in some cases was severe or resulted in death.

Some patients treated with Crixivan have had liver problems including liver failure and death. Some patients had other illnesses or were taking other drugs. It is uncertain if Crixivan caused these liver problems.

Diabetes and high blood sugar (hyperglycemia) have occurred in patients taking protease inhibitors. In some of these patients, this led to ketoacidosis, a serious condition caused by poorly controlled blood sugar. Some patients had diabetes before starting protease inhibitors, others did not. Some patients required adjustments to their diabetes medication. Others needed new diabetes medication.

In some patients with hemophilia, increased bleeding has been reported.

Severe muscle pain and weakness have occurred in patients taking protease inhibitors, including Crixivan, together with some of the cholesterol-lowering medicines called "statins". Call your doctor if you develop severe muscle pain or weakness.

Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck ("buffalo hump"), breast, and around the trunk. Loss of fat from the legs, arms and face may also happen. The cause and long term health effects of these conditions are not known at this time.

In some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from opportunistic infections may occur when combination antiretroviral treatment is started.

Clinical Studies

Increases in bilirubin (one laboratory test of liver function) have been reported in approximately 14% of patients. Usually, this finding has not been associated with liver problems. However, on rare occasions, a person may develop yellowing of the skin and/or eyes.

Side effects occurring in 2% or more of patients included: abdominal pain, fatigue or weakness, low red blood cell count, flank pain, painful urination, feeling unwell, nausea, upset stomach, diarrhea, vomiting, acid regurgitation, increased or decreased appetite, back pain, headache, dizziness, taste changes, rash, itchy skin, yellowing of the skin and/or eyes, upper respiratory infection, dry skin, and sore throat.

Swollen kidneys due to blocked urine flow occurred rarely.

Marketing Experience

Other side effects reported since Crixivan has been marketed include: allergic reactions; severe skin reactions; yellowing of the skin and/or eyes; heart problems including heart attack; stroke; abdominal swelling; indigestion; inflammation of the kidneys; decreased kidney function; inflammation of the pancreas; joint pain; depression; itching; hives; change in skin color; hair loss; ingrown toenails with or without infection; crystals in the urine; painful urination; numbness of the mouth; increased cholesterol; pain and difficulty moving shoulder.

Tell your doctor promptly about these or any other unusual symptoms. If the condition persists or worsens, seek medical attention.

How should I store Crixivan capsules?


This medication was prescribed for your particular condition. Do not use it for any other condition or give it to anybody else. Keep Crixivan and all medicines out of the reach of children. If you suspect that more than the prescribed dose of this medicine has been taken, contact your local poison control center or emergency room immediately.

This leaflet provides a summary of information about Crixivan. If you have any questions or concerns about either Crixivan or HIV, talk to your doctor.

Distributed by:

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Whitehouse Station, NJ 08889, USA

For patent information: www.merck.com/product/patent/home.html

The trademarks depicted herein are owned by their respective companies.

Copyright © 1996-2016 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

All rights reserved.

Revised 09/2016

usppi-mk0639-c-1609r018

NDC 0006-0571-43

Crixivan ®

(Indinavir Sulfate) Capsules

200 mg

ALERT

Find out about medicines that should NOT be taken

with Crixivan.

Note to Pharmacist:

Do not cover ALERT box with Pharmacy label.

Each capsule contains indinavir 200 mg (corresponding to indinavir

sulfate 250 mg). Store in a tightly closed container at room

temperature,15-30°C (59-86°F). Protect from moisture.

Crixivan Capsules are sensitive to

moisture and should be dispensed and

stored in the original container.

The desiccant should remain in the

original bottle.

USUAL

Dosage: See Package Insert.

Rx only

360 Capsules

Lot

Exp.

NDC 0006-0573-62

Crixivan ®

(Indinavir Sulfate) Capsules

400 mg

ALERT

Find out about medicines that should NOT be taken

with Crixivan.

Note to Pharmacist:

Do not cover ALERT box with Pharmacy label.

Each capsule contains indinavir 400 mg (corresponding to indinavir

sulfate 500 mg). Store in a tightly closed container at room

temperature,15-30°C (59-86°F).

Protect from moisture. Crixivan Capsules

are sensitive to moisture and should be

dispensed and stored in the original

container. The desiccant should remain

in the original bottle.

USUAL

Dosage: See Package Insert.

Rx only

180 Capsules

Lot

Exp.

Crixivan pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Crixivan available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Crixivan destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Crixivan Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Crixivan pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

References

  1. Dailymed."CRIXIVAN (INDINAVIR SULFATE) CAPSULE [MERCK SHARP & DOHME CORP.]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "indinavir". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "indinavir". http://www.drugbank.ca/drugs/DB0022... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Crixivan?

Depending on the reaction of the Crixivan after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Crixivan not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Crixivan addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Crixivan, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Crixivan consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 19 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2024 "sdrugs.com". All Rights Reserved